[Gene therapy for retinal dystrophies].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
Peter Charbel IssaRobert E Maclaren

Abstract

Genetic mutations are the cause of inherited retinal dystrophies. The underlying genetic basis of these diseases suggests that a gene therapy approach is logical either to replace or reduce the expression of defective genes. The first proof-of-concept clinical studies in patients with Leber's congenital amaurosis have suggested that retinal gene therapy is safe and potentially effective, at least for specific disease entities. In contrast to pharmacological treatment gene therapy has the advantage of being able to express a protein within specific cell populations and is a potentially definitive therapy. Besides replacing deficient genes in inherited diseases, additional strategies that might broaden the application of retinal gene therapy are also being developed. These include the permanent expression of neuroprotective substances or photosensitive molecules (so-called optogenetics). This overview discusses the current clinical strategies and potential problems of retinal gene therapy.

References

Jun 13, 2002·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·F C SchlichtenbredeM B Reichel
Feb 24, 2005·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·W K Schwerdtfeger
Mar 23, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·H Bolz
Jul 2, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·R FriggC E Remé
Jul 14, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·J NeidhardtB Klöckener-Gruissem
Nov 30, 2007·Current Gene Therapy·Prateek K BuchRobin R Ali
Apr 17, 2008·The Journal of Clinical Investigation·Mariacarmela AlloccaAlberto Auricchio
Apr 29, 2008·The New England Journal of Medicine·Albert M MaguireJean Bennett
Apr 29, 2008·The New England Journal of Medicine·James W B BainbridgeRobin R Ali
Sep 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Artur V CideciyanWilliam W Hauswirth
Aug 14, 2009·The New England Journal of Medicine·Artur V CideciyanSamuel G Jacobson
Dec 3, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Francesca SimonelliAlberto Auricchio
Dec 17, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·M Schüssler-Lenz, C K Schneider
Dec 17, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·S SchüleG Narayanan
Jan 6, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Matthew L HirschR Jude Samulski
Apr 7, 2010·Progress in Retinal and Eye Research·Wolfgang BergerJohn Neidhardt
Aug 18, 2010·Current Gene Therapy·Birgit LorenzKnut Stieger
Sep 30, 2010·PloS One·Peter Charbel IssaHendrik P N Scholl
Jun 29, 2011·Current Opinion in Neurobiology·Volker Busskamp, Botond Roska
Jul 13, 2011·Clinical & Experimental Ophthalmology·Peter Charbel Issa, Robert E MacLaren
Feb 22, 2012·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C M Poloschek, H Jägle

❮ Previous
Next ❯

Citations

Jan 9, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·J RosbachA Mirshahi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

The New England Journal of Medicine
Artur V CideciyanSamuel G Jacobson
Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society
Fowzan S Alkuraya
Human Gene Therapy
Connie L Cepko, Luk H Vandenberghe
© 2022 Meta ULC. All rights reserved